Literature DB >> 29705023

Lower dopamine tone in the striatum is associated with higher body mass index.

Ying Lee1, Nils B Kroemer2, Liane Oehme3, Bettina Beuthien-Baumann3, Thomas Goschke4, Michael N Smolka5.   

Abstract

Existing literature suggests that striatal dopamine (DA) tone may be altered in individuals with higher body mass index (BMI), but evidence accrued so far only offers an incomplete view of their relationship. Here, we characterized striatal DA tone using more comprehensive measures within a larger sample than previously reported. In addition, we explored if there was a relationship between striatal DA tone and disinhibited eating. 60 healthy participants underwent a 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine (18F-DOPA) positron emission tomography (PET) scan. Disinhibited eating was measured with the Three-Factor Eating Questionnaire on a baseline visit. Individual whole-brain PET parameter estimates, namely 18F-DOPA influx rate constant (kocc i.e. DA synthesis capacity), 18F-DA washout rate (kloss) and effective distribution volume ratio (EDVR= kocc/ kloss), were derived with a reversible-tracer graphical analysis approach. We then computed parameter estimates for three regions-of-interests (ROIs), namely the ventral striatum, putamen and caudate. Overweight/mildly obese individuals had lowered EDVR than normal weight individuals in all three ROIs. The most prominent of these associations, driven by lowered kocc (r = -.28, p = .035) and heightened kloss (r = .48, p < .001), was found in the ventral striatum (r = -.46, p < .001). Disinhibition was greater in higher-BMI individuals (r = .31, p = .015), but was unrelated to PET measures and did not explain the relationship between PET measures and BMI. In sum, our findings resonate with the notion that overweight/mildly obese individuals have lower striatal DA tone and suggest new avenues for investigating their underlying mechanisms.
Copyright © 2018 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Keywords:  Body mass index; Dopamine; Fluorodopa F 18; Overweight; Positron-emission tomography; Striatum

Mesh:

Substances:

Year:  2018        PMID: 29705023     DOI: 10.1016/j.euroneuro.2018.03.009

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  6 in total

1.  Mesolimbic opioid-dopamine interaction is disrupted in obesity but recovered by weight loss following bariatric surgery.

Authors:  Henry K Karlsson; Lauri Tuominen; Semi Helin; Paulina Salminen; Pirjo Nuutila; Lauri Nummenmaa
Journal:  Transl Psychiatry       Date:  2021-05-01       Impact factor: 6.222

Review 2.  Dopaminergic Control of the Feeding Circuit.

Authors:  Ja-Hyun Baik
Journal:  Endocrinol Metab (Seoul)       Date:  2021-04-06

3.  L-DOPA administration shifts the stability-flexibility balance towards attentional capture by distractors during a visual search task.

Authors:  T Goschke; M N Smolka; P Riedel; I M Domachowska; Y Lee; P T Neukam; L Tönges; S C Li
Journal:  Psychopharmacology (Berl)       Date:  2022-02-11       Impact factor: 4.530

Review 4.  Molecular Imaging of Central Dopamine in Obesity: A Qualitative Review across Substrates and Radiotracers.

Authors:  Lieneke Katharina Janssen; Annette Horstmann
Journal:  Brain Sci       Date:  2022-04-08

5.  Obesity and dietary fat influence dopamine neurotransmission: exploring the convergence of metabolic state, physiological stress, and inflammation on dopaminergic control of food intake.

Authors:  Conner W Wallace; Steve C Fordahl
Journal:  Nutr Res Rev       Date:  2021-06-28       Impact factor: 8.146

6.  Higher Urinary Dopamine Concentration is Associated with Greater Ad Libitum Energy Intake in Humans.

Authors:  Alessio Basolo; Takafumi Ando; Tim Hollstein; Susanne B Votruba; Jonathan Krakoff; Paolo Piaggi
Journal:  Obesity (Silver Spring)       Date:  2020-04-14       Impact factor: 9.298

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.